An analysis of the attrition of drug candidates from four major pharmaceutical companies
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to have a significant effect on attrition rates and that additional work is required to address safety-related failures. Further cross-company collaborations will be crucial to future progress in this area.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advancing drug safety assessment relies on bridging the translation gap between animal toxicology findings and clinical outcomes, a challenge with far-reaching consequences for R&D efficiency, regulatory success and patient safety (Waring et al., 2015; Amorim et al., 2024).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Waring et al., 2015
In the citing paper
“When using a polylactic acid–polyethylene glycol copolymer, the embedding rate reached 90%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“Su et al. found that, when polylactic acid was used as the membrane material, the embedding rate of hemoglobin was very low, only 7.9%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“The attrition rates in Phase II and Phase III development stages have been reported to be as high as 80% [75,344].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [75]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Self-citationLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
Self-citation
Cited by
Items 701–800 of 1,001
Arya, C. G., Kumari, J., Kishan, J., Goswami, K., Sriram, D., Salim, S. A., Pakhira, P., Busi, S., Alharbi, M., Chandrakanth, M., et al. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.141693 · Cited by 13
Dindar, Z., Anbaraki, A., Hosseini, S. S., Harati, Z., Bahrami, A., Balalaie, S., Ghobeh, M., Mahdavi, M., & Seyedarabi, A. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00768 · Cited by 13
DILI prediction in drug development: present and future
Uetrecht, J. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2495955 · Cited by 13
Multiscale-Information-Embedded Universal Toxicity Prediction Framework
Wu, L., Wang, F., Zhang, Y., Li, R., Zhao, Y., Xu, H., Gao, Z., He, S., & Bo, X. (2025) · Environmental Science & Technology · doi:10.1021/acs.est.5c04614 · Cited by 13
What Happens in Successful Optimizations? A Survey of 2018–2024 Literature
Leeson, P. D. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03171 · Cited by 13
Self-citationDrug Development 101: A Primer
Buckley, L. A., Bebenek, I., Cornwell, P. D., Hodowanec, A. C., Jensen, E. C., Murphy, C., & Ghantous, H. N. (2020) · International Journal of Toxicology · doi:10.1177/1091581820939083 · Cited by 13
Lamichhane, A., Thakuri, P. S., Nejad, P. R., & Tavana, H. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211014185 · Cited by 13
Nájera, G. S., Narganes-Carlón, D., & Crowther, D. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-94897-9 · Cited by 13
Arora, D., & Khurana, B. (2022) · Springer eBooks · doi:10.1007/978-981-16-5180-9_7 · Cited by 13
Kelsall, K. N., Foroughi, L. M., Frank, D. S., Schenck, L., LaBuda, A., & Matzger, A. J. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00970 · Cited by 13
Di, L. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2238606 · Cited by 13
Rao, M. S., McDuffie, E., Srivastava, S., Plaisted, W. C., & Sachs, C. W. (2024) · Pharmaceuticals · doi:10.3390/ph17070875 · Cited by 13
The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice
Dickie, A. P., Wilson, C. E., Schreiter, K., Wehr, R., Wilson, E. M., Bial, J., Scheer, N., Wilson, I. D., & Riley, R. J. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.03.015 · Cited by 13
Hatley, R. J. D., Macdonald, S. J. F., Slack, R. J., Le, J., Ludbrook, S. B., & Lukey, P. T. (2017) · Angewandte Chemie · doi:10.1002/ange.201707948 · Cited by 13
Cabrera, N., Mora, J. R., & Márquez, E. (2019) · Journal of Chemistry · doi:10.1155/2019/2954250 · Cited by 13
Emon, M. A., Domingo‐Fernándéz, D., Hoyt, C. T., & Hofmann‐Apitius, M. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03568-5 · Cited by 13
Wright, M. R. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1787-8_21 · Cited by 13
Eriksen, J. B., Christiansen, J. J., Bauer‐Brandl, A., Ruponen, M., Rautio, J., & Brandl, M. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106366 · Cited by 13
Molecular Aspects of Histamine Receptors
Mocking, T. A. M., Bosma, R., Rahman, S. N., Verweij, E. W. E., McNaught-Flores, D. A., Vischer, H. F., & Leurs, R. (2016) · The Receptors · doi:10.1007/978-3-319-40308-3_1 · Cited by 13
Shi, J., & Zha, W. (2018) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-018-0503-9 · Cited by 13
Jeong, C. G., Negro, G. D., Getsios, S., & Ekert, J. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813671-3.00005-0 · Cited by 13
Turning Metabolomics into Drug Discovery
Boufridi, A., & Quinn, R. J. (2016) · Journal of the Brazilian Chemical Society · doi:10.5935/0103-5053.20160083 · Cited by 13
CADD medicine: design is the potion that can cure my disease
Manas, E. S., & Green, D. V. S. (2017) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-016-0004-3 · Cited by 13
Assessment of polymeric mucin–drug interactions
Kishimoto, H., Ridley, C. E., Inoue, K., & Thornton, D. J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306058 · Cited by 12
Nakai, K., Miki, K., Kikuchi, T., & Yamano, M. (2024) · Crystal Growth & Design · doi:10.1021/acs.cgd.4c01421 · Cited by 12
Toward Integrative Predictive Toxicology: Advanced Methods for Drug Toxicity and Safety Prediction
Gianquinto, E., Bersani, M., Armando, L. G., Davani, L., Cena, C., Simone, A. D., & Spyrakis, F. (2026) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.70065 · Cited by 12
Drug Discovery and Development
Link, W. (2019) · Springer eBooks · doi:10.1007/978-3-030-18722-4_4 · Cited by 12
Microphysiological Systems: A Pathologist’s Perspective
Sura, R., Vleet, T. V., & Berridge, B. R. (2020) · Veterinary Pathology · doi:10.1177/0300985820908794 · Cited by 12
Kaczmarczyk, J. A., Roberts, R. R., Luke, B. T., Chan, K. C., Wagoner, C. M. V., Felder, R. A., Saul, R. G., Colantonio, S., & Blonder, J. (2021) · Oncotarget · doi:10.18632/oncotarget.28072 · Cited by 12
Du, B.-X., Xu, Y., Yiu, S., Yu, H., & Shi, J. (2023) · Lecture notes in computer science · doi:10.1007/978-3-031-29119-7_6 · Cited by 12
Bodun, D. S., Omoboyowa, D. A., Olofinlade, V. F., Ayodeji, A. O., Mauri, A., Ogbodo, U. C., & Balogun, T. A. (2025) · In Silico Pharmacology · doi:10.1007/s40203-024-00300-6 · Cited by 12
Drug Repositioning for COVID-19
Benavides-Córdoba, V. (2020) · Colombia medica · doi:10.25100/cm.v51i2.4279 · Cited by 12
Cao, M., Chen, Y., Zhao, T., Wei, S., Guo, M., & Zhai, X. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115715 · Cited by 12
Muñoz, J. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252533 · Cited by 12
Fang, H., & Jiang, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687291 · Cited by 12
Antona, A., Varalda, M., Roy, K., Favero, F., Mazzucco, E., Zuccalà, M., Leo, G., Soggia, G., Bettio, V., Tosi, M., et al. (2022) · Cancers · doi:10.3390/cancers14030776 · Cited by 12
Wilson, J. L., Gravina, A., & Grimes, K. (2022) · Integrative Biology · doi:10.1093/intbio/zyac002 · Cited by 12
Adepoju, A. J., Latona, D. F., Olafare, O. G., Oyebamiji, A. K., Abdul-Hammed, M., & Semire, B. (2022) · Analele Universităţii "Ovidius" Constanţa. Seria Chimie/"Ovidius" University Annals of Chemistry · doi:10.2478/auoc-2022-0004 · Cited by 12
Santoro, A. L., Carrilho, E., Lanças, F. M., & Montanari, C. A. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.12.009 · Cited by 12
Safavi, M., Sabourian, R., & Abdollahi, M. R. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1217196 · Cited by 12
In Silico Systems Pharmacology to Assess Drug's Therapeutic and Toxic Effects
Aguayo‐Orozco, A., Audouze, K., Brunak, S., & Taboureau, O. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160907093215 · Cited by 12
PatchSearch: A Fast Computational Method for Off-Target Detection
Rasolohery, I., Moroy, G., & Guyon, F. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00529 · Cited by 12
Prediction of Human Liver Toxicity Using In Vitro Assays: Limitations and Opportunities
Atienzar, F., & Nicolas, J.-M. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-7677-5_7 · Cited by 12
4 Ds in health research—working together toward rapid precision medicine
Niederberger, E., Parnham, M. J., Maas, J., & Geißlinger, G. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910917 · Cited by 12
Foulkes, M. J., Tolliday, F. H., Henry, K. M., Renshaw, S. A., & Jones, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240231 · Cited by 12
Deep Learning-based Modeling for Preclinical Drug Safety AssessmentPreprint
Jaume, G., de Brot, S., Song, A. H., Williamson, D. F. K., Oldenburg, L., Zhang, A., Chen, R. J., Asín, J., Blatter, S., Dettwiler, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.20.604430 · Cited by 12
L’intelligence artificielle, une révolution dans le développement des médicaments
Moingeon, P. E., Garbay, C., Dahan, M., Fermont, I., Benmakhlouf, A., Gouyette, A., Poitou, P., Saint-Pierre, A., & pharmaceutiques, L. G. D. V. I. E. S. (2024) · médecine/sciences · doi:10.1051/medsci/2024028 · Cited by 11
Deng, G., Shi, C., Ge, R., Hu, R., Wang, C., Qin, F., Pan, C., Mao, H., & Yang, Q. K. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1553743 · Cited by 11
Dhiman, P., Das, S., Pathania, V., Rawat, S., Nandanwar, H. S., Thakur, K. G., & Chaudhari, V. D. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02207 · Cited by 11
Braddick, H. J., Tipping, W. J., Grant, E. K., Tomkinson, N. C. O., Faulds, K., & Graham, D. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00748h · Cited by 11
Understanding drug-target residence time and the implications on drug discovery
Liu, H., Zhong, H., & Guo, D. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2619070 · Cited by 11
Accelerating Leigh syndrome drug discovery through deep learning screening in brain organoids
Menacho, C., Okawa, S., Álvarez‐Merz, I., Wittich, A., Muñoz‐Oreja, M., Lisowski, P., López-Martín, M., Pentimalli, T. M., Zakin, S., Thevandavakkam, M. A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71391-2 · Cited by 11
Charlie Gard and the Limits of Parental Authority
Caplan, A. L., & Folkers, K. M. (2017) · The Hastings Center Report · doi:10.1002/hast.772 · Cited by 11
Aleo, M. D., Doshna, C. M., Baltrukonis, D. J., Fortner, J. H., Drupa, C. A., Navetta, K. A., Fritz, C. A., Potter, D. M., Verdugo, M. E., & Beierschmitt, W. P. (2019) · Journal of Applied Toxicology · doi:10.1002/jat.3822 · Cited by 11
Chomchoei, C., Brimson, J. M., & Brimson, S. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2166829 · Cited by 11
Torres, L. H. M., Arrais, J. P., & Ribeiro, B. (2023) · Neural Computing and Applications · doi:10.1007/s00521-023-08403-5 · Cited by 11
Gómara-Lomero, M., Calleja, A. I. L., Rezusta, A., Aínsa, J. A., & Ramón‐García, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-39647-9 · Cited by 11
El-Sayed, N. N. E., Al-Otaibi, T. M., Barakat, A., Almarhoon, Z. M., Hassan, M. Z., Al‐Zaben, M. I., Krayem, N., Masand, V. H., & Bacha, A. G. B. (2023) · Pharmaceuticals · doi:10.3390/ph16101392 · Cited by 11
Heyrati, M. P., Ghorbanali, Z., Akbari, M., Pishgahi, G., & Zare‐Mirakabad, F. (2023) · ACS Omega · doi:10.1021/acsomega.3c05778 · Cited by 11
Montejo-López, W., Sampieri-Cabrera, R., Nicolás‐Vázquez, M. I., Aceves-Hernández, J. M., & Razo‐Hernández, R. S. (2024) · RSC Advances · doi:10.1039/d3ra07380g · Cited by 11
Domain-adversarial multi-task framework for novel therapeutic property prediction of compounds
Xie, L., He, S., Zhang, Z., Lin, K., Bo, X., Yang, S. H., Feng, B., Wan, K., Yang, K., Yang, J., et al. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa063 · Cited by 11
One‐Step Synthesis of Photoaffinity Probes for Live‐Cell MS‐Based Proteomics
Fallon, D. J., Lehmann, S., Chung, C., Phillipou, A., Eberl, C., Fantom, K. G. M., Zappacosta, F., Patel, V. K., Bantscheff, M., Schofield, C. J., et al. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202102036 · Cited by 11
Pharmacokinetic Tools and Applications
Madden, J. C., & Thompson, C. V. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1960-5_3 · Cited by 11
Nanotechnological application of peptide- and protein-based therapeutics
Awuchi, C. G., Akram, M., Owuamanam, C. I., Ogueke, C. C., Awuchi, C. G., & Twinomhwezi, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824408-1.00005-3 · Cited by 11
Far, B. F., Safaei, M., Mokhtari, F., Fallahi, M. S., & Naimi‐Jamal, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02026-5 · Cited by 11
Mochel, J. P., Ward, J. L., Blondel, T., Kundu, D., Merodio, M. M., Zemirline, C., Guillot, E., Giebelhaus, R. T., de la Mata, A. P., Iennarella‐Servantez, C. A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-71202-y · Cited by 11
Roy, A., & Chaguturu, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801814-9.00003-9 · Cited by 11
Integral estimation of xenobiotics’ toxicity with regard to their metabolism in human organism
Dmitriev, A. V., Rudik, A. V., Filimonov, D. A., Lagunin, A. A., Pogodin, P. V., Dubovskaja, V., Bezhentsev, V., Ivanov, S. M., Druzhilovskiy, D. S., Tarasova, O. A., et al. (2017) · Pure and Applied Chemistry · doi:10.1515/pac-2016-1205 · Cited by 11
Kenna, J. G., Waterton, J. C., Baudy, A. R., Galetin, A., Hines, C. D. G., Hockings, P. D., Patel, M. R., Scotcher, D., Sourbron, S. P., Ziemian, S., et al. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-7677-5_30 · Cited by 11
Collier, P. N., Panchagnula, A., O’Dowd, H., LeTiran, A., & Aronov, A. M. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00530 · Cited by 11
Nayyab, S., Naureen, H., Maryam, A., Attar, R., Sabitaliyevich, U. Y., Konysbayevna, K. K., & Farooqi, A. A. (2020) · Cellular and Molecular Biology · doi:10.14715/cmb/2020.66.6.27 · Cited by 11
Phenotypic Drug Discovery: History, Evolution, Future
Swinney, D. C. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160721-00001 · Cited by 11
Lipid Membrane Alterations in Tumor Spheroids Revealed by Fluorescence Lifetime Microscopy Imaging
Peng, X., Huang, J., Li, M., Chen, Z., Yan, W., & Qu, J. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c05126 · Cited by 11
Bonaccorsi, S. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837673476-00461 · Cited by 10
Neural organoids as advanced tools for neurotoxicity modeling
Majumder, J., & Murphy, W. L. (2025) · Current Research in Toxicology · doi:10.1016/j.crtox.2025.100249 · Cited by 10
von Raumer, M., & Hilfiker, R. (2018) · Wiley eBooks · doi:10.1002/9783527697847.ch1 · Cited by 10
Riccio, F., Micarelli, E., Secci, R., Giuliani, G., Vumbaca, S., Massacci, G., Castagnoli, L., Fuoco, C., & Cesareni, G. (2022) · Cell Death Discovery · doi:10.1038/s41420-021-00811-7 · Cited by 10
Fang, H. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac379 · Cited by 10
Improving on in-silico prediction of oral drug bioavailability
Alqahtani, S. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2261366 · Cited by 10
AI-driven GPCR analysis, engineering, and targeting
Velloso, J. P. L., Kovacs, A. S., Pires, D. E. V., & Ascher, D. B. (2024) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102427 · Cited by 10
Consideration of the Root Causes in Candidate Attrition During Oncology Drug Development
Kuo, Y., & Barrett, J. S. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1464 · Cited by 10
ADME Optimization in Drug Discovery
McGinnity, D. F., & Grime, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12365-0 · Cited by 10
One-pot parallel synthesis of 1,3,5-trisubstituted 1,2,4-triazoles
Radchenko, D. S., Naumchyk, V., Dziuba, I., Kyrylchuk, A. A., Gubina, K. E., Moroz, Y. S., & Grygorenko, O. O. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10218-2 · Cited by 10
Omidkhah, N., Eisvand, F., Hadizadeh, F., Zarghi, A., & Ghodsi, R. (2022) · ChemistrySelect · doi:10.1002/slct.202201239 · Cited by 10
Large-scale prediction of adverse drug reactions-related proteins with network embedding
Park, J., Lee, S.-Y., Kim, K., Jung, J., & Lee, D. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac843 · Cited by 10
Synthetic hydrazones: In silico studies and in vitro evaluation of the antileishmania potential
de Sousa, V. C., de Carvalho, R. D. C. V., Barcelar, K. G. D. R., de Melo, D. S., Nunes, J. M., Sousa, P. S. D. A., Rocha, J. A., Lima, C. C., Gonsalves, A. D. A., Araújo, C. R. M., et al. (2023) · Toxicology in Vitro · doi:10.1016/j.tiv.2023.105560 · Cited by 10
Cell painting transfer increases screening hit rate
Cohen, E., Corbé, M., Franco, C. A., Vasconcelos, F. F., Perez, F., Nery, E. D., Bollot, G., & Genovesio, A. (2023) · Biological Imaging · doi:10.1017/s2633903x23000077 · Cited by 10
Cannon, A. E., Zürrer, W. E., Zejlon, C., Kulcsár, Z., Lewandowski, S. A., Piehl, F., Granberg, T., & Ineichen, B. V. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1135282 · Cited by 10
Web Services for the Prediction of ADMET Parameters Relevant to the Design of Neuroprotective Drugs
Perkin, V. O., Antonyan, G. V., Radchenko, E. V., & Palyulin, V. A. (2023) · Neuromethods · doi:10.1007/978-1-0716-3311-3_16 · Cited by 10
Ligand-Binding Kinetics on Histamine Receptors
Bosma, R., Mocking, T. A. M., Leurs, R., & Vischer, H. F. (2017) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-6843-5_5 · Cited by 10
Improving machine learning in early drug discovery
Bendtsen, C., Degasperi, A., Ahlberg, E., & Carlsson, L. (2017) · Annals of Mathematics and Artificial Intelligence · doi:10.1007/s10472-017-9541-2 · Cited by 10
Malhotra, S., Mugumbate, G., Blundell, T. L., & Higueruelo, A. P. (2017) · Database · doi:10.1093/database/bax041 · Cited by 10
Fey, S. J., Korzeniowska, B., & Wrzesinski, K. (2020) · Toxicology Research · doi:10.1093/toxres/tfaa033 · Cited by 10
Pharmaceutical technologies with potential application to insecticide discovery†
Wing, K. D. (2020) · Pest Management Science · doi:10.1002/ps.6075 · Cited by 10
Mohanan, A., Melge, A. R., & Mohan, C. G. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.10.015 · Cited by 10
Coors, A., Falkenhain, A., Scheurer, M., & Länge, R. (2021) · Environmental Toxicology and Chemistry · doi:10.1002/etc.5018 · Cited by 10
Characterizing interdisciplinarity in drug research: A translational science perspective
Li, X., & Tang, X. (2021) · Journal of Informetrics · doi:10.1016/j.joi.2021.101216 · Cited by 10
Machine Learning Applied to the Modeling of Pharmacological and ADMET Endpoints
Göller, A. H., Kuhnke, L., ter Laak, A., Meier, K., & Hillisch, A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1787-8_2 · Cited by 10
Cardiovascular Drugs: an Insight of In Silico Drug Design Tools
Sarma, H., Upadhyaya, M., Gogoi, B., Phukan, M., Kashyap, P., Das, B., Devi, R., & Sharma, H. K. (2021) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-021-09587-w · Cited by 10
Dilly, S. J., & Morris, G. S. (2017) · Current Drug Discovery Technologies · doi:10.2174/1570163814666170117120005 · Cited by 10
Metadata
- Authors
- Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., Wallace, O., & Weir, A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Thomson Reuters (United Kingdom) (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Pfizer (United Kingdom) (GB)
- Eli Lilly (United States) (US)
- Corresponding author
- Waring, Michael J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-06-19
- Volume
- 14
- Issue
- 7
- Pages
- 475-486
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1663154925
- Cited by
- 1,450
- References
- 27
- Citations by year
- 2026: 164 · 2025: 116 · 2024: 148 · 2023: 143 · 2022: 140 · 2021: 131 · 2020: 129 · 2019: 129 · 2018: 129 · 2017: 113 · 2016: 94 · 2015: 11
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- drug attrition, small molecule drug candidates, physicochemical properties, clinical failure, drug safety, compound optimization, oral medication, pharmaceutical industry
- MeSH terms
- Animals, Drug Industry, Drug Evaluation, Preclinical, Humans, Statistics as Topic, Drugs, Investigational, Drug Delivery Systems, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.